PURPOSE: Augmentation has been known as the major complication of long-term dopaminergic treatment of restless legs syndrome (RLS). However, there have been no reports on the prevalence of augmentation in Korea. Thus, we aimed to assess the rate of augmentation and evaluate related factors in Korean RLS patients. METHODS: Ninety-four idiopathic RLS patients who have been treated over a period of at least 6 months were enrolled. Thirty subjects were treated with a dopamine agonist only, and 64 were treated with a dopamine agonist and alpha two delta ligands. We assessed the clinical characteristics of those RLS subjects and evaluated the rate of augmentation. Augmentation was assessed using the NIH criteria for augmentation by two RLS experts independently. RESULTS: Eleven subjects (11.7%) were classified as having definitive or highly suggestive clinical indication of augmentation. In comparing the augmentation group with the non-augmentation group, there were no significant differences of baseline clinical characteristics. Four (13.3%) of the dopamine agonists monotherapy group and seven (10.9%) of the combination therapy group were categorized as augmentation. There was no significant difference in the augmentation rate between these two groups. CONCLUSIONS: We found an 11.7% augmentation rate in Korean RLS subjects. There was no difference in the rate of RLS augmentation between the dopaminergic monotherapy group and the combined treatment group. It may be related with using a similar dosage of dopaminergic drugs.
PURPOSE: Augmentation has been known as the major complication of long-term dopaminergic treatment of restless legs syndrome (RLS). However, there have been no reports on the prevalence of augmentation in Korea. Thus, we aimed to assess the rate of augmentation and evaluate related factors in Korean RLS patients. METHODS: Ninety-four idiopathic RLS patients who have been treated over a period of at least 6 months were enrolled. Thirty subjects were treated with a dopamine agonist only, and 64 were treated with a dopamine agonist and alpha two delta ligands. We assessed the clinical characteristics of those RLS subjects and evaluated the rate of augmentation. Augmentation was assessed using the NIH criteria for augmentation by two RLS experts independently. RESULTS: Eleven subjects (11.7%) were classified as having definitive or highly suggestive clinical indication of augmentation. In comparing the augmentation group with the non-augmentation group, there were no significant differences of baseline clinical characteristics. Four (13.3%) of the dopamine agonists monotherapy group and seven (10.9%) of the combination therapy group were categorized as augmentation. There was no significant difference in the augmentation rate between these two groups. CONCLUSIONS: We found an 11.7% augmentation rate in Korean RLS subjects. There was no difference in the rate of RLS augmentation between the dopaminergic monotherapy group and the combined treatment group. It may be related with using a similar dosage of dopaminergic drugs.
Authors: R Nisha Aurora; David A Kristo; Sabin R Bista; James A Rowley; Rochelle S Zak; Kenneth R Casey; Carin I Lamm; Sharon L Tracy; Richard S Rosenberg Journal: Sleep Date: 2012-08-01 Impact factor: 5.849
Authors: Clete Kushida; Marie Martin; Prashant Nikam; Bonnie Blaisdell; Gene Wallenstein; Luigi Ferini-Strambi; John E Ware Journal: Qual Life Res Date: 2007-02-01 Impact factor: 4.147
Authors: Richard P Allen; Crystal Chen; Diego Garcia-Borreguero; Olli Polo; Sarah DuBrava; Jeffrey Miceli; Lloyd Knapp; John W Winkelman Journal: N Engl J Med Date: 2014-02-13 Impact factor: 91.245
Authors: Diego García-Borreguero; Richard P Allen; Ralf Kohnen; Birgit Högl; Claudia Trenkwalder; Wolfgang Oertel; Wayne A Hening; Walter Paulus; David Rye; Arthur Walters; Juliane Winkelmann; Christopher J Earley Journal: Sleep Med Date: 2007-06-01 Impact factor: 3.492
Authors: Birgit Högl; Diego García-Borreguero; Ralf Kohnen; Luigi Ferini-Strambi; Georgios Hadjigeorgiou; Magdolna Hornyak; Al de Weerd; Svenja Happe; Karin Stiasny-Kolster; Viola Gschliesser; Renata Egatz; Birgit Frauscher; Heike Benes; Claudia Trenkwalder; Wayne A Hening; Richard P Allen Journal: J Neurol Date: 2009-09-11 Impact factor: 4.849
Authors: Guang Jian Liu; Lang Wu; Song Lin Wang; Li Ding; Li Li Xu; Yun Fu Wang; Li Ying Chang Journal: Medicine (Baltimore) Date: 2016-01 Impact factor: 1.817